The pharmacokinetics of diminazene aceturate after intramuscular administration in healthy dogs
Journal of the South African Veterinary Association
| Field | Value | |
| Title | The pharmacokinetics of diminazene aceturate after intramuscular administration in healthy dogs | |
| Creator | Miller, D.M. Swan, G.E. Lobetti, R.G. Jacobson, L.S. | |
| Description | The pharmacokinetics of diminazene aceturate following intramuscular (i.m.) administration at 4.2 mg/kg was evaluated in 8 healthy German Shepherd dogs. Blood samples were collected at 19 intervals over a period of 21 days. Diminazene plasma concentrations were measured using a validated HPLC method with UV detection and a sensitivity of 25 ng/m . The in vitro and in vivo binding of diminazene to blood elements was additionally determined. Diminazene pharmacokinetics showed a large inter-individual variation after i.m. administration. It had a short absorption half-life (K01-HL of 0.11 + 0.18 h), resulting in a Cmax of 1849 + 268.7 ng/mℓ at Tmax of 0.37 h and a mean overall elimination half-life (T1/2ß) of 5.31 + 3.89 h. A terminal half-life of 27.5 + 25.0 h was measured. At 1 h after i.m. injection, 75% of the diminazene in whole blood was in the plasma fraction. The results of this study indicate that diminazene is rapidly distributed and sequestered into the liver, followed by a slower terminal phase during which diminazene is both redistributed to the peripheral tissues and/or renally excreted. It is recommended that diminazene administered i.m. at 4.2 mg/kg should not be repeated within a 21-day period. | |
| Publisher | AOSIS | |
| Date | 2005-06-14 | |
| Identifier | 10.4102/jsava.v76i3.416 | |
| Source | Journal of the South African Veterinary Association; Vol 76, No 3 (2005); 146-150 2224-9435 1019-9128 | |
| Language | eng | |
| Relation |
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:
https://jsava.co.za/index.php/jsava/article/view/416/402
|
|
ADVERTISEMENT
